Great Valley Advisor Group, Inc. Summit Therapeutics Inc. Transaction History
Great Valley Advisor Group, Inc.
- $3.84 Billion
- Q3 2024
A detailed history of Great Valley Advisor Group, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 25,000 shares of SMMT stock, worth $446,750. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,000
Previous 34,023
26.52%
Holding current value
$446,750
Previous $265,000
106.42%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$436 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.2 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$62 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...